Visterra adds $8.1m to Series A, in-licenses dengue program
This article was originally published in Scrip
Executive Summary
Visterra raised another $8.1m in venture capital that brings its Series A round to $34.2m and licensed a dengue virus program from the Massachusetts Institute of Technology (MIT) to expand its antibody therapeutics pipeline for infectious diseases.